Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02608385 | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | active not recruiting | Phase 1 | 117 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04706715 | LAG3 PET Imaging in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 41 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05704985 |
| Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors |
| active not recruiting |
| Phase 1 |
| 39 |
| DEKA BiosciencesINDUSTRY |
| 1 |
| May 29, 2025 |
| clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05167071 | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | active not recruiting | Phase 1 | 53 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT04877717 | A Study of SHR-A1904 in Patients With Advanced Solid Cancer | active not recruiting | Phase 1 | 107 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04643574 | NeoTIL in Advanced Solid Tumors | active not recruiting | Phase 1 | 42 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05862324 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)(TACTIC-3) | active not recruiting | Phase 1 / Phase 2 | 113 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Feb 14, 2025 | clinicaltrials |
| NCT05580991 | Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors | active not recruiting | Phase 1 | 27 | Canwell Biotech LimitedINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT03791112 | A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor | active not recruiting | Phase 1 | 54 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT06723964 | A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors | active not recruiting | Phase 1 | 35 | AP Biosciences Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05990452 | Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 261 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06026254 | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial | active not recruiting | Phase 1 | 2 | ImmuneSensor Therapeutics Inc.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05278546 | A Study of ILB2109 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 | 48 | Innolake BiopharmINDUSTRY | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT04492488 | A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer | active not recruiting | Phase 1 / Phase 2 | 129 | Shanghai Miracogen Inc.INDUSTRY | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT02521844 | A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | active not recruiting | Phase 1 | 89 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 2 | Oct 8, 2024 | clinicaltrials |
| NCT05765032 | Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 220 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05878691 | A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. | active not recruiting | Phase 1 | 320 | Glenmark Specialty S.A.INDUSTRY | 2 | Jul 22, 2024 | clinicaltrials |
| NCT04592653 | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)(ARTISTRY-3) | active not recruiting | Phase 1 / Phase 2 | 78 | Mural Oncology, IncINDUSTRY | 2 | Jun 7, 2024 | clinicaltrials |
| NCT05621486 | A Clinical Study to Evaluate B4T2-001 CAR T Cells in the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Shanghai East HospitalOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02193503 | MVX-ONCO-1 in Patients With Solid Tumor | active not recruiting | Phase 1 | 34 | Maxivax SAINDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2025source: clinicaltrials